Outcomes in COVID-19 dolutegravir studies

0 0.5 1 1.5+ All studies -15% 2 1K Improvement, Studies, Patients Relative Risk Mortality -202% 1 93 Cases -20% 1 156 RCTs -202% 1 93 Prophylaxis -14% 1 1K Late -202% 1 93 Dolutegravir for COVID-19 c19early.org November 2025 Favorsdolutegravir Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Abbaspou.. (DB RCT) -202% 3.02 [0.13-72.3] death 1/46 0/47 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.5 Late treatment -202% 3.02 [0.13-72.3] 1/46 0/47 202% higher risk Verburgh -14% 1.14 [0.75-1.72] death/hosp. 626 (n) 881 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.54 Prophylaxis -14% 1.14 [0.75-1.72] 626 (n) 881 (n) 14% higher risk All studies -15% 1.15 [0.78-1.71] 1/672 0/928 15% higher risk 2 dolutegravir COVID-19 studies c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.49 Effect extraction pre-specified(most serious outcome) Favors dolutegravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Abbaspou.. (DB RCT) -202% 3.02 [0.13-72.3] 1/46 0/47 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.5 Late treatment -202% 3.02 [0.13-72.3] 1/46 0/47 202% higher risk All studies -202% 3.02 [0.13-72.3] 1/46 0/47 202% higher risk 1 dolutegravir COVID-19 mortality result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.5 Favors dolutegravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Abbaspou.. (DB RCT) -202% 3.02 [0.13-72.3] death 1/46 0/47 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.5 Late treatment -202% 3.02 [0.13-72.3] 1/46 0/47 202% higher risk Verburgh -14% 1.14 [0.75-1.72] death/hosp. 626 (n) 881 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.54 Prophylaxis -14% 1.14 [0.75-1.72] 626 (n) 881 (n) 14% higher risk All studies -15% 1.15 [0.78-1.71] 1/672 0/928 15% higher risk 2 dolutegravir COVID-19 serious outcomes c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.49 Effect extraction pre-specified(most serious outcome) Favors dolutegravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Verburgh -20% 1.20 [0.38-3.85] cases 45 (n) 111 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.75 Prophylaxis -20% 1.20 [0.38-3.85] 45 (n) 111 (n) 20% higher risk All studies -20% 1.20 [0.38-3.85] 45 (n) 111 (n) 20% higher risk 1 dolutegravir COVID-19 case result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.75 Favors dolutegravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Abbaspou.. (DB RCT) -202% 3.02 [0.13-72.3] death 1/46 0/47 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.5 Late treatment -202% 3.02 [0.13-72.3] 1/46 0/47 202% higher risk All studies -202% 3.02 [0.13-72.3] 1/46 0/47 202% higher risk 1 dolutegravir COVID-19 Randomized Controlled Trial c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.5 Effect extraction pre-specified(most serious outcome) Favors dolutegravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Abbaspou.. (DB RCT) -202% 3.02 [0.13-72.3] 1/46 0/47 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.5 Late treatment -202% 3.02 [0.13-72.3] 1/46 0/47 202% higher risk All studies -202% 3.02 [0.13-72.3] 1/46 0/47 202% higher risk 1 dolutegravir COVID-19 RCT mortality result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.5 Favors dolutegravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Abbaspou.. (DB RCT) -202% 3.02 [0.13-72.3] death 1/46 0/47 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.5 Late treatment -202% 3.02 [0.13-72.3] 1/46 0/47 202% higher risk Verburgh -14% 1.14 [0.75-1.72] death/hosp. 626 (n) 881 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.54 Prophylaxis -14% 1.14 [0.75-1.72] 626 (n) 881 (n) 14% higher risk All studies -15% 1.15 [0.78-1.71] 1/672 0/928 15% higher risk 2 dolutegravir COVID-19 peer reviewed studies c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.49 Effect extraction pre-specified(most serious outcome) Favors dolutegravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Abbaspou.. (DB RCT) -202% 3.02 [0.13-72.3] death 1/46 0/47 Improvement, RR [CI] Treatment Control Abbaspou.. (DB RCT) 5% 0.95 [0.52-1.75] oxygen 14/46 15/47 Verburgh -14% 1.14 [0.75-1.72] death/hosp. 626 (n) 881 (n) Verburgh -20% 1.20 [0.38-3.85] cases 45 (n) 111 (n) Dolutegravir COVID-19 outcomes c19early.org November 2025 Favors dolutegravir Favors control